 Kimberly Simmons
Concepts (123)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 31 | 2026 | 3819 | 3.640 |
Why?
| | Autoantibodies | 12 | 2025 | 1482 | 1.930 |
Why?
| | Insulin-Secreting Cells | 5 | 2023 | 388 | 1.500 |
Why?
| | Antibodies, Monoclonal, Humanized | 6 | 2026 | 917 | 1.260 |
Why?
| | Autoimmunity | 4 | 2026 | 917 | 0.680 |
Why?
| | Diet, Ketogenic | 1 | 2021 | 37 | 0.670 |
Why?
| | Diet, Carbohydrate-Restricted | 1 | 2021 | 37 | 0.670 |
Why?
| | Prediabetic State | 1 | 2023 | 253 | 0.650 |
Why?
| | HLA-DQ beta-Chains | 1 | 2020 | 59 | 0.640 |
Why?
| | Health Fairs | 1 | 2019 | 10 | 0.620 |
Why?
| | Insulin | 5 | 2023 | 2492 | 0.570 |
Why?
| | Celiac Disease | 2 | 2022 | 301 | 0.520 |
Why?
| | Endocrinology | 3 | 2024 | 77 | 0.510 |
Why?
| | Child | 23 | 2026 | 22562 | 0.500 |
Why?
| | Insulin Antibodies | 1 | 2016 | 103 | 0.490 |
Why?
| | Adolescent | 19 | 2026 | 22326 | 0.460 |
Why?
| | Dried Blood Spot Testing | 1 | 2016 | 125 | 0.460 |
Why?
| | Blood Glucose | 2 | 2026 | 2304 | 0.440 |
Why?
| | HLA-D Antigens | 1 | 2014 | 30 | 0.430 |
Why?
| | Diet Therapy | 1 | 2014 | 37 | 0.430 |
Why?
| | Antibodies | 1 | 2015 | 400 | 0.400 |
Why?
| | Islets of Langerhans | 5 | 2024 | 818 | 0.370 |
Why?
| | Bone Density | 1 | 2015 | 499 | 0.350 |
Why?
| | Mass Screening | 1 | 2019 | 1325 | 0.330 |
Why?
| | Child, Preschool | 11 | 2026 | 11634 | 0.330 |
Why?
| | Humans | 35 | 2026 | 142526 | 0.320 |
Why?
| | Immunosuppressive Agents | 1 | 2014 | 859 | 0.300 |
Why?
| | Diabetes Complications | 2 | 2022 | 222 | 0.300 |
Why?
| | Infant | 10 | 2026 | 9908 | 0.290 |
Why?
| | Diabetic Ketoacidosis | 3 | 2025 | 210 | 0.270 |
Why?
| | Hypoglycemic Agents | 2 | 2023 | 1391 | 0.250 |
Why?
| | Thyroiditis, Autoimmune | 1 | 2026 | 15 | 0.240 |
Why?
| | Risk Assessment | 3 | 2023 | 3562 | 0.240 |
Why?
| | Thyroid Gland | 1 | 2026 | 92 | 0.230 |
Why?
| | Disease Progression | 5 | 2024 | 2831 | 0.230 |
Why?
| | Hypothyroidism | 1 | 2026 | 74 | 0.230 |
Why?
| | HLA Antigens | 2 | 2025 | 232 | 0.230 |
Why?
| | Male | 15 | 2026 | 70910 | 0.220 |
Why?
| | Young Adult | 6 | 2026 | 13878 | 0.220 |
Why?
| | Age of Onset | 3 | 2025 | 545 | 0.210 |
Why?
| | Female | 15 | 2026 | 76624 | 0.210 |
Why?
| | Obesity Management | 1 | 2020 | 8 | 0.170 |
Why?
| | Hyperglycemia | 1 | 2024 | 365 | 0.170 |
Why?
| | Consensus | 4 | 2024 | 546 | 0.160 |
Why?
| | Diagnostic Techniques, Endocrine | 1 | 2019 | 14 | 0.150 |
Why?
| | Blood Specimen Collection | 1 | 2019 | 37 | 0.150 |
Why?
| | Clinical Protocols | 1 | 2021 | 274 | 0.150 |
Why?
| | Glucose Tolerance Test | 1 | 2020 | 367 | 0.150 |
Why?
| | Quality of Life | 2 | 2023 | 3064 | 0.150 |
Why?
| | Methylation | 1 | 2019 | 239 | 0.150 |
Why?
| | Haplotypes | 1 | 2020 | 491 | 0.140 |
Why?
| | Nutritional Status | 1 | 2021 | 358 | 0.140 |
Why?
| | Cell Death | 1 | 2019 | 389 | 0.130 |
Why?
| | Community Health Services | 1 | 2019 | 234 | 0.130 |
Why?
| | Disease Susceptibility | 1 | 2019 | 353 | 0.130 |
Why?
| | Alleles | 1 | 2020 | 885 | 0.130 |
Why?
| | Hypophosphatemia | 1 | 2017 | 17 | 0.130 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2016 | 28 | 0.130 |
Why?
| | Radioimmunoassay | 1 | 2016 | 168 | 0.130 |
Why?
| | Risk | 1 | 2019 | 905 | 0.130 |
Why?
| | Colorado | 3 | 2024 | 4638 | 0.120 |
Why?
| | Caregivers | 1 | 2025 | 954 | 0.120 |
Why?
| | Infant Formula | 1 | 2017 | 71 | 0.120 |
Why?
| | Adult | 5 | 2026 | 39715 | 0.120 |
Why?
| | Bone Diseases | 1 | 2017 | 65 | 0.120 |
Why?
| | Disease Management | 1 | 2020 | 641 | 0.120 |
Why?
| | Influenza, Human | 1 | 2022 | 635 | 0.120 |
Why?
| | Patient Education as Topic | 1 | 2021 | 779 | 0.120 |
Why?
| | Practice Guidelines as Topic | 1 | 2023 | 1552 | 0.120 |
Why?
| | Prospective Studies | 2 | 2026 | 7862 | 0.110 |
Why?
| | Pediatrics | 2 | 2024 | 1110 | 0.110 |
Why?
| | Abatacept | 1 | 2014 | 56 | 0.110 |
Why?
| | Patient Reported Outcome Measures | 1 | 2019 | 458 | 0.110 |
Why?
| | Vitamin B Complex | 1 | 2014 | 40 | 0.110 |
Why?
| | Early Medical Intervention | 1 | 2014 | 60 | 0.100 |
Why?
| | Niacinamide | 1 | 2014 | 82 | 0.100 |
Why?
| | Diabetic Nephropathies | 1 | 2017 | 302 | 0.100 |
Why?
| | Health Status | 1 | 2019 | 822 | 0.100 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2019 | 717 | 0.100 |
Why?
| | Prevalence | 3 | 2026 | 2817 | 0.100 |
Why?
| | Pediatric Obesity | 1 | 2020 | 617 | 0.100 |
Why?
| | Secondary Prevention | 1 | 2014 | 241 | 0.100 |
Why?
| | Immunoconjugates | 1 | 2014 | 128 | 0.100 |
Why?
| | Autoantigens | 1 | 2015 | 427 | 0.100 |
Why?
| | Primary Prevention | 1 | 2014 | 202 | 0.100 |
Why?
| | Chronic Disease | 1 | 2019 | 1815 | 0.090 |
Why?
| | B-Lymphocytes | 1 | 2017 | 875 | 0.090 |
Why?
| | Genetic Predisposition to Disease | 2 | 2025 | 2388 | 0.090 |
Why?
| | Treatment Outcome | 1 | 2026 | 11298 | 0.080 |
Why?
| | Autoimmune Diseases | 1 | 2014 | 467 | 0.080 |
Why?
| | Cross-Sectional Studies | 2 | 2025 | 5700 | 0.080 |
Why?
| | Middle Aged | 3 | 2025 | 35049 | 0.070 |
Why?
| | Risk Factors | 1 | 2023 | 10593 | 0.070 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2014 | 1642 | 0.070 |
Why?
| | Biomarkers | 1 | 2019 | 4207 | 0.070 |
Why?
| | Societies, Medical | 2 | 2024 | 866 | 0.060 |
Why?
| | Sensitivity and Specificity | 2 | 2022 | 1977 | 0.060 |
Why?
| | Receptors, Antigen, T-Cell | 2 | 2022 | 720 | 0.060 |
Why?
| | Infant, Newborn | 1 | 2015 | 6324 | 0.050 |
Why?
| | CD3 Complex | 1 | 2023 | 107 | 0.050 |
Why?
| | C-Peptide | 1 | 2023 | 171 | 0.050 |
Why?
| | Seroepidemiologic Studies | 1 | 2023 | 170 | 0.050 |
Why?
| | T-Lymphocytes | 2 | 2023 | 2016 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell, alpha-beta | 1 | 2022 | 335 | 0.040 |
Why?
| | Perception | 1 | 2023 | 378 | 0.040 |
Why?
| | Databases, Factual | 1 | 2026 | 1458 | 0.040 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2022 | 546 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2023 | 2007 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2023 | 664 | 0.040 |
Why?
| | International Cooperation | 1 | 2018 | 195 | 0.030 |
Why?
| | ROC Curve | 1 | 2019 | 600 | 0.030 |
Why?
| | Rickets | 1 | 2017 | 10 | 0.030 |
Why?
| | Aged | 1 | 2016 | 25117 | 0.030 |
Why?
| | Phosphorus | 1 | 2017 | 99 | 0.030 |
Why?
| | Alkaline Phosphatase | 1 | 2017 | 146 | 0.030 |
Why?
| | Anxiety | 1 | 2023 | 1087 | 0.030 |
Why?
| | Parents | 1 | 2023 | 1450 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 2081 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2019 | 2980 | 0.020 |
Why?
| | Calcium | 1 | 2017 | 1179 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1353 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2019 | 5994 | 0.010 |
Why?
| | Animals | 1 | 2015 | 37697 | 0.010 |
Why?
|
|
Simmons's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|